Comparison of a Novel Tazarotene 0.045% Lotion to Tazarotene 0.1% Cream: Patient-Reported Outcomes from a Phase 2 Clinical Trial

Zoe Draelos; Fran Cook-Bolden; Lawrence Green; Eric Guenin; Gina Martin; Radhakrishnan Pillai

doi:10.25251/skin.3.supp.9

Zoe Draelos

Dermatology Consulting Services, PLLC, High Point, NC

Fran Cook-Bolden

Dept. of Dermatology, Mount Sinai Hospital Center, New York, NY

Lawrence Green

Dept. of Dermatology, George Washington University School of Medicine, Washington, DC

Eric Guenin

Ortho Dermatologics, Bridgewater, NJ

Gina Martin

Bausch Health Americas Inc., Petaluma, CA

Radhakrishnan Pillai

Bausch Health Americas Inc., Petaluma, CA

Keywords

acne, tazarotene

Abstract

Abstract not available.

References

1. Zaenglein AL, et al. J Am Acad Dermatol. 2016;74(5):945-973.

2. Tanghetti EA, et al. J Drugs Dermatol. 2019;18(6):542-548.

Poster PDF

Published

Nov 9, 2019

DOI https://doi.org/10.25251/skin.3.supp.9

How to Cite

Draelos, Z., Cook-Bolden, F., Green, L., Guenin, E., Martin, G., & Pillai, R. (2019). Comparison of a Novel Tazarotene 0.045% Lotion to Tazarotene 0.1% Cream: Patient-Reported Outcomes from a Phase 2 Clinical Trial. SKIN The Journal of Cutaneous Medicine, 3, S9. https://doi.org/10.25251/skin.3.supp.9

Issue

Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas

Section

Acne & Rosacea

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Mark Lebwohl, Leon Kircik, Angela Moore, Linda Stein Gold, James Del Rosso, Zoe Draelos, Melinda Gooderham, Lawrence Green, Adelaide Herbert, Kim Papp, Jerry Bagel, Neal Bhatia, Laura Ferris, Terry Jones, Steve Kempers, David Pariser, Paul Yamauchi, Matthew Zirwas, Amy Feng, Patrick Burnett, Robert Higham, David Berk, Once-Daily Roflumilast Cream 0.3%, a Potent Phosphodiesterase-4 Inhibitor, Provided Safe and Effective Treatment of Psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Linda Stein Gold, Mark Lebwohl, Kim Papp, Melinda Gooderham, Leon Kircik, Zoe Draelos, Steven Kempers, David Pariser, Javier Alonso-Llamazares, Darryl Toth, Kathleen Smith, Robert Higham, Lynn Navale, Howard Welgus, David Berk, Roflumilast Cream (ARQ-151) Improved Itch Severity and Itch-Related Sleep Loss in Adults With Chronic Plaque Psoriasis in a Phase 2b Study , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Leon Kircik, Mark Lebwohl, Kim Papp, Melinda Gooderham, Linda Stein Gold, Zoe Draelos, Steven Kempers, Stephen Tyring, Lorne Albrecht, Marni Wiseman, Laura Ferris, Kathleen Smith, Robert Higham, Lynn Navale, Howard Welgus, David Berk, Roflumilast Cream (ARQ-151) 0.15% and 0.3% Improved Burden of Signs and Symptoms in Adults With Chronic Plaque Psoriasis in a Phase 2b Study , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Linda Stein Gold, Andrew Blauvelt, April Armstrong , Seemal Desai, Howard Sofen, Lawrence Green, Steve Tyring, Laura Ferris, Philip Brown, David Rubenstein, Stephen Piscitelli, Anna Tallman, Leon Kircik, Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Secondary Efficacy Outcomes from Two Pivotal Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Angela Moore, Suzanne Bruce, Neil Sadick, Eduardo Tschen, Philip Werschler, Sunil Dhawan, Douglas Farsha, Michael Gold, Scott Guenthner, Steve Kempers, Leon Kircik, Jennifer Parish, Marta Rendon, Phoebe Rich, Linda Stein-Gold, Stephen Tyring, Robert Weiss, Adnan Nasir, Carsten Schmitz, Terry Boodhoo, Alexandre Kaoukhov, David Berk, Fran Cook-Bolden, Ayman Grada, Once-Daily Oral Sarecycline 1.5 mg/kg/day is Effective for Moderate to Severe Acne Vulgaris: Results from Two 12-Week, Phase 3, Randomized, Double-Blind Clinical Trials , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
Javier Alonso-Llamazares, Melinda Gooderham, Jerry Bagel, John Browning, Zoe Draelos, Kimberly Grande, Adelaide Herbert, Wei Jing Loo, Chih-ho Hong, Mark Lebwohl, Walter Nahm, Kim Papp, David Pariser, Jennifer Soung, Linda Stein Gold, Irina Turchin, Amy Feng, Patrick Burnett, Robert Higham, David Berk, Roflumilast Cream 0.3% Improved the Severity and Impact of Itch in Patients With Chronic Plaque Psoriasis in the Phase 3 DERMIS-1 and DERMIS-2 Studies , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
James Del Rosso, Jeffrey Sugarman , Michael Gold, Krysten Arekapdui, Lawrence Green, A New Frontier in Acne Treatment: Encapsulated Benzoyl Peroxide and Tretinoin , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
James Del Rosso, Leon Kircik, Linda Stein Gold, Hilary Baldwin, Jonathan Weiss, David Pariser, Valerie Callender, Edward Lain, Michael Gold, Kenneth Beer, Zoe Draelos, Neil Sadick, ; Radhakrishnan Pillai, Varsha Bhatt, Emil Tanghetti, Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: Phase 2 Study of the First Triple-Combination Drug , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Linda Stein Gold, Mark Lebwohl, Neal Bhatia, Douglas DiRuggiero, Abby Jacobson, Radhakrishnan Pillai, Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Matthew Zirwas, Zoe Draelos, Janet Dubois, Leon Kircik, Angela Moore, Linda Stein Gold, Javier Alonso-Llamazares, Michael Bukhalo, Suzanne Bruce, Kimmie Eads, Lawrence Green, Scott Guenthner, Laura Ferris, Seth Forman, Steven Kempers, Edward Lain, Charles Lynde, David Pariser, David Pariser, Darryl Toth, paul Yamauchi, Patrick Burnett, David Berk, A Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)

1 2 3 4 5 6 7 8 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Similar Articles

Most read articles by the same author(s)